^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    3d
    REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors (clinicaltrials.gov)
    P=N/A, N=240, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • raludotatug deruxtecan (DS-6000)
    5d
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin
    5d
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    5d
    Intergroup statement: opportunistic salpingectomy-molecular pathology, clinical outcomes and implications for practice (German Ovarian Cancer Commission, the North-Eastern German Society of Gynecologic Oncology (NOGGO), AGO Austria and AGO Swiss). (PubMed, Arch Gynecol Obstet)
    This review examines the current status of molecular pathology studies, recent evidence on the clinical implications of STIC, new data on the use of opportunistic salpingectomy, and published patient outcomes since then. The question of whether the potential benefit of opportunistic salpingectomy, outweighs the potential harms associated with surgical morbidity, which have not been conclusively excluded, should be revisited in light of these recent data.
    Clinical data • Review • Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    TP53 mutation
    6d
    HIPEC: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    11d
    Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, University of California, Davis | Trial completion date: Jul 2027 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Dec 2025
    Trial completion date • Trial primary completion date • HEOR
    |
    CD4 (CD4 Molecule)
    14d
    A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov)
    P3, N=300, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • topotecan • trastuzumab rezetecan (SHR-A1811)
    14d
    A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, AbbVie
    New P2 trial
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    19d
    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Pfizer | N=400 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Zirabev (bevacizumab-bvzr)
    20d
    Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Rutgers, The State University of New Jersey | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2025 --> Jul 2025
    Enrollment closed • Trial primary completion date
    25d
    Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | N=75 --> 12
    Trial completion • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B)
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)
    28d
    Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment (clinicaltrials.gov)
    P=N/A, N=28, Recruiting, Mayo Clinic
    New trial
    28d
    NRG-GY021: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov)
    P2, N=61, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Feb 2026
    Trial completion date • Tumor mutational burden
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Lynparza (olaparib) • Imjudo (tremelimumab-actl)
    28d
    Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study. (PubMed, Int J Gynecol Cancer)
    This real-world study reported a homologous recombination deficiency prevalence of 56.0% (ranging from 52.0% to 58.5%) across Asia, the Middle East, and Russia. Our results highlight the unmet need to implement guideline-recommended testing and real-world data collection for all patients newly diagnosed with advanced high-grade epithelial ovarian cancer to optimize treatment strategies.
    Journal • BRCA Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    29d
    Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer (clinicaltrials.gov)
    P3, N=166, Not yet recruiting, Jina Pharmaceuticals Inc.
    New P3 trial
    |
    paclitaxel
    1m
    Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) (clinicaltrials.gov)
    P3, N=616, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2027 --> Oct 2028
    Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • docetaxel
    1m
    BP1001-A-101-GynOnc: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Oct 2024 --> Oct 2027 | Trial primary completion date: Jul 2024 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    paclitaxel
    1m
    NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    1m
    Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/homologous Recombination Deficiency Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, University of Colorado, Denver
    New P1 trial
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • cirtuvivint (SM08502)
    1m
    An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Roswell Park Cancer Institute
    New trial
    1m
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1m
    HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=468, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • GSK5733584
    1m
    NRG-GY027: Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Feb 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • NF1 (Neurofibromin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TSC1 (TSC complex subunit 1) • AKT1S1 (AKT1 Substrate 1)
    |
    HRD
    |
    carboplatin • paclitaxel • ipatasertib (RG7440)
    1m
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    1m
    SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Shanghai Gynecologic Oncology Group
    New P1 trial • IO biomarker
    1m
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jan 2025 --> May 2025
    Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)
    1m
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=78, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • raludotatug deruxtecan (DS-6000)
    1m
    NRG-GY003: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    1m
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    2ms
    Paraneoplastic Neurologic Syndrome Associated with Fallopian Tube Cancer: A Case Report. (PubMed, Case Rep Oncol)
    After surgery, intravenous immunoglobulin and glucocorticoid treatment, the oncological response was satisfactory, but the neurological symptoms did not improve. This case illustrates the importance of considering a paraneoplastic etiology in patients with unexplained neurological manifestations and emphasized the necessity of appropriate management and early treatment of the primary malignancy.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    2ms
    PARPi and Ovarian Cancer Survival (clinicaltrials.gov)
    P=N/A, N=6000, Not yet recruiting, Shanghai Gynecologic Oncology Group
    New trial
    2ms
    TOAST IT: Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (clinicaltrials.gov)
    P1, N=2, Terminated, Mayo Clinic | Trial completion date: Jan 2025 --> Oct 2024 | Active, not recruiting --> Terminated; slow accrual
    Trial completion date • Trial termination
    |
    cisplatin • doxorubicin hydrochloride • daunorubicin
    2ms
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    2ms
    Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P3 trial
    |
    paclitaxel • IBI-354
    2ms
    OSU-20277: Hyperthermic Intraperitoneal Chemotherapy with Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel
    2ms
    A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    paclitaxel • topotecan • trastuzumab rezetecan (SHR-A1811)
    2ms
    NCI-2018-00438: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=25, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion • PARP Companion diagnostic
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)
    2ms
    Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2027 | Trial primary completion date: Oct 2024 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    RAD51 (RAD51 Homolog A)
    |
    Talzenna (talazoparib)
    2ms
    Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer (clinicaltrials.gov)
    P3, N=538, Recruiting, Women's Hospital School Of Medicine Zhejiang University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel
    2ms
    HIPEC: Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (clinicaltrials.gov)
    P2, N=10, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> May 2025
    Trial completion date • Trial primary completion date • HEOR
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin
    2ms
    BCBOvaire: Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Jan 2027 --> Jul 2032 | Trial primary completion date: Jan 2027 --> Jul 2027
    Trial completion date • Trial primary completion date